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Abstract: The availability of donor organs continues to be insufficient to meet the needs of 
patients actively waiting for transplant. Consequently, there is continuing pressure to increase 
the donor organ pool while simultaneously assuring safety for the recipient population. The 
complication of donor malignancy transmission has been documented almost from the beginning 
of transplantation, and continues to be a concern today. The anecdotal nature of case reports and 
compiled series ensures that clinical decisions related to organ use from donors with malignancy 
will of necessity continue to be made on the basis of low-level evidence. Despite this limitation, 
the literature indicates that not all donor neoplasms have the same risk for transmission to the 
recipient, and it is necessary to consider the specific malignancy affecting the donor, as well as 
the condition of the recipient, before a decision is made to transplant or discard a given organ. 
Published cases suggest that certain forms of neoplasia, such as melanoma, choriocarcinoma, 
sarcoma, small cell carcinoma, or metastatic carcinomas serve as strong contraindications to 
organ donation. In contrast, considerable experience exists to suggest that certain tumors of the 
central nervous system, small subclinical prostate carcinomas, or small renal cell carcinomas 
resected prior to transplant, among other tumors, should not in themselves disqualify an indi-
vidual from donating organs in the appropriate circumstance. This review presents the case for 
considering organ transplantation in the setting of certain donor malignancies and discusses 
factors to be weighed in such decisions. Additionally, donors with a history of cancer are 
considered, and features that may aid in reaching a conclusion for or against transplantation of 
organs from these patients are presented.
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Introduction
Organ transplantation has undergone remarkable progress over the past several decades. 
However, this major undertaking is by no means risk-free, and among many potential 
complications, the possibility exists that organ engraftment might be accompanied by 
the inadvertent transfer of disease, including malignancy, from donor to recipient. This 
problem has been acknowledged since the early days of modern transplantation1–4 and a 
system of checks and balances has evolved over the years to ensure that such events are 
rare. Nevertheless, isolated episodes of tumor transmission continue to occur,  usually 
accompanied by significant morbidity or mortality, and often attracting the glare of 
negative publicity, potentially distorting public perception regarding transplantation 
in general. Because the supply of donor organs continues to be inadequate to meet 
current patient needs,5 increased attention is being devoted to “high-risk” donors, 
including those with existing or historical malignant disease.
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Herein we will consider the issue of organ transplant 
from potential donors with malignancy. At the outset we 
distinguish donor-transmitted tumors from donor-derived 
tumors.6 The latter would include, for example, post-
 transplant lymphoproliferative disorders of donor cell origin, 
or late-onset neoplasms that arise from allografted donor 
cells. In post-transplant lymphoproliferative disorders, the 
process is entirely post-transplant and no tumor existed in 
the donor. In the case of late-onset tumors (such as 10 years 
post-transplant), estimated tumor doubling times suggest that 
no mass lesion existed at the time of transplant. Therefore, 
tumor development, albeit donor-derived, proceeded entirely 
or almost entirely in the post-transplant period. Unfortunately, 
there is no convenient lower time limit by which one can 
segregate these cases from those in which a small tumor may 
have been present at transplant and therefore transmitted with 
the organ. For convenience, we will consider donor-origin 
tumors arising within a 2-year post-transplant period as most 
likely representing donor-transmitted tumors.
It is not our intent to present a comprehensive list-
ing of tumors, because several reports have provided this 
perspective.7,8 Rather, we will provide a general background 
and discuss some of the more commonly encountered tumor 
types. Broadly accepted consensus statements regarding 
donor malignancy screening, cancer transmission risk and 
recipient selection issues, and optimum screening and man-
agement of recipients at risk for or with donor-transmitted 
cancer are needed, but do not yet exist. For now, we ask 
the reader to reflect on his or her own position in such 
situations.
General considerations
It should be obvious that there is no single correct answer 
to the question posed in the title of this article. Rather, 
every donor-recipient combination presents a unique set of 
circumstances that challenges the transplant surgeon to for-
mulate a sound clinical plan. Specific information regarding 
Table 1 Items to consider in the setting of a potential organ donor with active or historical neoplasia
Donor-related Active tumor What is the specific type of tumor?
what is the extent of tumor, ie, tumor stage?
what is the risk of tumor transmission based on current available evidence?
Historical tumor All of the above and also:
How long ago did the tumor occur? what is the tumor-free interval?
Is this tumor associated with late recurrence? what is the expected 5-year disease-free survival?
Recipient- 
related
what is the desire of the potential recipient? Is there a clear understanding of the risks involved?
what type of post-transplant screening would be appropriate in this circumstance? For how long?
what treatment options are available if tumor is transferred?
what are the alternatives for this patient if transplantation is deferred because of concerns about tumor transmission?
both the donor tumor and issues of recipient concern should 
be obtained. Some suggested items to consider are listed 
in Table 1.
When considering the possibility of utilizing organs from 
a donor with known malignant disease, two obvious general 
questions are first, whether the organs should be used at all, 
and second, to whom they should be offered.
The first question requires, among other things, that the 
risk of transmission should be evaluable. The level of evi-
dence on which to base this estimate is low, based mainly 
on anecdotal reports and collected series. Unfortunately, it 
is likely to remain in that form for some time to come due to 
the nature of the subject. Regardless, experience has shown 
that some tumor types appear to be associated with a high 
transmissibility rate which, although not precisely definable, 
is sufficient to defend the position that patients with such 
tumors (eg, melanoma, sarcoma, metastatic carcinoma) are 
currently not eligible to serve as organ donors.7–11
The second question also requires clinical judgment based 
on a near absence of high level evidence. Specifically, one 
must balance both the risk of transmission and the associated 
morbidity and mortality of tumor development against the 
estimated life expectancy on the waiting list and likelihood 
of receiving another offer of a donor organ from a nontumor-
bearing donor. Prognostic scores, such as the Model for 
End-stage Liver Disease12 and its pediatric counterpart or 
their more recent variants13 may be useful to estimate short-
term survival in potential liver recipients. Analogous efforts 
have been put forth to predict survival in renal transplant 
candidates.14,15
For those recipients who do develop cancer, widely 
available statistical data16 may provide a starting point for 
survival estimates. However, a recent study has indicated 
that stage-specific outcomes for individual cancers may 
be worse in transplant patients compared with the general 
population,17 and this should factor into the decision-making 
process.
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Given these complexities, the final decision whether or 
not to utilize any organ in a particular circumstance must 
ultimately remain a clinical one, made by the transplant 
surgeon in combination with an informed patient.
Frequency of malignancy  
in the donor population
Several reports have estimated the frequency of donor 
 malignancies in various settings. Birkeland and Storm18 
estimated an overall 1.3% frequency in a Danish population-
based study of 626 donors. However, that study aggregated 
both post-transplant living donor tumors and historical 
tumors, along with those found at the time of donation, 
and the actual risk of donor tumor present and undetected 
at time of transplant was 2/626 or 0.3%. Myron Kauffman 
et al6 estimated a donor frequency rate of 0.04% based on a 
cohort of 34,933 cadaveric donors. Because this study relied 
on voluntary reporting by transplant centers, the possibility 
of underreporting must be considered. Nevertheless, both 
studies point to a frequency of unexpected donor malignancy 
of much less than 1% of the donor population.
These numbers should be considered in the context of 
several qualifications. First, the donor selection process 
typically excludes many individuals with various underly-
ing conditions, including malignancies. Therefore, these 
figures, which represent our best estimates as based on 
actual donor populations, may not reflect the incidence of 
unexpected neoplasia in the general population. Sens et al19 
performed a retrospective review of 412 mainly forensic 
autopsies and found unexpected cancer in 29 patients 
(7.0%). Although 12 of these 29 patients had other 
 obvious conditions that would preclude organ donation, the 
authors estimated that 17 (4.1%) were presumably able to 
serve as organ donors.
Second, general population figures may provide insight 
into the overall magnitude of the problem, but the possibility 
of neoplasia in any given donor should be evaluated in light 
of the appropriate reference population. For example, Yin 
et al,20 looking at a cohort of 340 male donors, found prostate 
cancer in one of 203 donors 49 years of age or younger, but 
that number rose to 40 cancers in 137 donors when those 
older than 49 were considered.
The decision to use selected donors with cancer would 
theoretically be expected to have a small but measurable 
impact on the wait list, which is at 72,169 (active wait list) 
at the time of writing in March 2011.21 The most recent 
US figures (for the year 2007) showed 2,424,000 deaths,22 
of which 559,650 were cancer-related.23 In the same year, 
there were 8085 deceased donors who provided organs for 
22,056 transplants.24 If one makes the assumption that all 
organs from donors with cancer were declined, then there 
was approximately one deceased donor per 464 (noncancer) 
deaths. Applying this ratio to all cancer deaths would lead 
to an additional 1206 donors, and approximately 3290 
additional transplants. This significantly overestimates 
the actual number of potential additional donors, given 
that many of these patients would be ineligible to provide 
organs. (A counterargument is that patients with cancer 
might be more inclined to serve as organ donors if given 
the opportunity, resulting in a higher rate of donation 
for eligible members of this group.) Nevertheless, even 
if 10% of such patients were able to donate organs, 
several hundred additional organ transplants might be 
performed annually.
Donor tumor transmission risk 
stratification and recipient safety
There have been several organized efforts at incorporating 
experience regarding donor tumor transmission risk into 
guidelines, policy, or resource documents. The Spanish 
National Transplant Organization25 and the Italian National 
Transplant Center26 defined separate guidelines for assess-
ing donors with malignancies, among other conditions. In 
2009 the Council of Europe published a Guide to Safety and 
 Quality Assurance for the Transplantation of Organs, Tissues 
and Cells, which included an addendum dealing specifically 
with criteria to apply in the case of donor malignancy.7
In the US, publications from the Organ Procurement and 
Transplantation Network/United Network for Organ Sharing 
(OPTN/UNOS) and the Israel Penn International Transplant 
Tumor Registry (IPITTR) have served to advise practice, in 
addition to the formal OPTN donor screening and reporting 
(Policy 4) requirements. Recently, the ad hoc Malignancy 
Subcommittee of the OPTN Disease Transmission Advisory 
Committee (DTAC) has published a resource document in 
which six risk categories for tumor transmission are defined 
and populated with specific tumor types.8
The approach in European countries has also recom-
mended specific cancer screening for donors. At this time in 
the US, specific screening tests for cancer, beyond assessment 
by history and examination at time of organ assessment, 
are not mandated. In an individual with no obvious tumor 
or history of tumor, questions such as test sensitivity and 
specificity, time involved, determination of which cancers 
to screen for and in whom, and plan of action in response 
to a positive screening test, would all require consensus 
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approaches to minimize the effects of false positive and false 
negative results.27
Specific tumor types
Central nervous system tumors
In 2010 the American Cancer Society recorded 22,020 new 
cases of central nervous system tumors, with an estimated 
13,140 deaths in the US. Earlier summaries of tumor registry 
reports by Penn and Buell9,28–30 concluded that, in light of the 
unmet patient need, organs from donors with central nervous 
system malignancies should not categorically be rejected, 
but should be offered to recipients with limited short-term 
life expectancy. This position was further qualified by their 
conclusion that the presence of prior ventriculoperitoneal 
shunt, craniotomy, chemotherapy, radiotherapy, or a high 
grade lesion (specifically medulloblastoma, astrocytoma 
grades III or IV, ie, glioblastoma multiforme) served as 
risk factors for transmission and would disqualify potential 
donation to even this limited recipient pool.
The World Health Organization (WHO) has recently 
updated the histologic classification of central nervous system 
tumors which distinguishes high grade (grades 3–4) from 
low grade (grades 1–2) lesions.31 Review of the literature 
of donor transmission of central nervous system tumors is 
problematic because, in addition to possible statistical bias, 
many reports either combine high and low grade tumors32,33 or 
aggregate all primary central nervous system tumors without 
specifying tumor type.34 Further, total numbers of organs or 
recipients from the given donor(s) are often not provided, 
hindering efforts at frequency estimates, and additional 
cofactors such as surgical interventions are not reported in 
a uniform fashion.
With these limitations in mind, we recently reviewed 
the literature and found reports concerning 85 donors with 
glioblastoma multiforme (Grade IV astrocytoma) of whom 
six were associated with a total of nine transmissions.8 
This occurred on a background of 145 reported organs 
transplanted into 142 reported recipients. These numbers 
represent minimum estimates because not all organs or 
recipients were explicitly stated in all reports. Other high 
grade tumors specifically reported included medulloblastoma 
(26 donors, four of whom were responsible for a total of six 
tumor transmissions in a minimum estimate of 53 organs 
transplanted into 43 recipients), malignant meningioma (one 
donor with transmission), and pineoblastoma and anaplastic 
ependymoma (one donor each, no transmissions). Low grade 
tumors included meningioma (21 donors with no transmis-
sion in a minimum of 35 reported recipients). Several reports 
of astrocytomas combined WHO categories I–III, with one 
transmission reported from a total of 70 donors who provided 
a minimum of 122 organs to 99 reported recipients.
Other issues may complicate decisions regarding triage 
of organs from donors with tumors involving the central 
nervous system. Penn35 originally pointed out the neces-
sity to distinguish primary from metastatic central nervous 
system tumors, with donors from the latter category almost 
guaranteed to have circulating tumor cells capable of being 
transmitted. This may be a particular issue with such tumors 
as choriocarcinoma or renal cell carcinoma.
In 2009, the European Union adopted the WHO classifica-
tion to segregate donor central nervous system tumors into 
three groups.7 Donors with WHO grades I or II central ner-
vous system tumors are considered eligible to donate organs. 
Donors with WHO Grade III tumors could be considered in 
emergency cases and with recipient consent, provided that 
other risk factors for transmission are absent. Donors with 
Grade IV central nervous system tumors are ineligible for 
organ donation, although the possibility of using such organs 
in case of “vital emergency” and with recipient consent was 
left open. More recently, the Malignancy Subcommittee of 
the DTAC committee of OPTN/UNOS8 took a similar but 
slightly more simplified approach, in which donors with 
WHO grade I or II central nervous system tumors were con-
sidered at low risk for transmission, and suggested that such 
organs may be usable for recipients at significant risk without 
transplant. In contrast, donors with high grade (WHO III or 
IV) central nervous system tumors, or any central nervous 
system tumor with shunt, surgery other than uncomplicated 
biopsy, radiation, or metastases outside of the central nervous 
system were considered at high risk for tumor transmission, 
and use of organs from these donors was discouraged except 
in rare and extreme circumstances. However, the subcommit-
tee acknowledged the fact that in some cases current opinion 
may overestimate the risk of transmission. Thus, prospective 
data collection is needed to determine more definitively the 
actual transmission rates of individual tumors, and future 
updates should reflect the best available data.
Renal cell carcinoma
In the US, the American Cancer Society estimated 58,240 
new cases of kidney and renal pelvis cancer, with an estimated 
13,040 deaths.16 Approximately 80% of these cases are due to 
renal cell carcinoma. Inadvertent transfer of renal carcinoma 
along with the renal allograft was among the earliest exam-
ples of malignancy transmission.1–3 Penn36,37  summarized 
the early experience, and originally  recommended that such 
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organs not be used for transplant. However, based on later 
experience he recommended that if small renal tumors could 
be excised completely, then the organ could be transplanted 
provided the patient was carefully followed for possible 
recurrence.35 The limited literature consists of examples 
of living kidney donors who had small renal tumors at the 
time of transplantation,38–42 series of deceased donors,43 or 
both living and deceased donors44 with such tumors. These 
reports support the position that resection of kidney tumor 
with subsequent kidney transplantation is compatible with 
long-term disease-free recipient survival, although the 
possibility of reporting bias must be borne in mind when 
considering retrospective anecdotal reports. Most recently, 
Brook et al45 reported a series of 43 renal transplant recipients 
who received organs from living donors with renal tumors 
less than 3 cm in diameter, and resected prior to transplant. 
They report one recurrence at 9 years and observed survival 
similar to that of conventional renal transplantation. These 
authors recommend this procedure for patients who would 
otherwise be unable to receive a transplant.
In a recent review of the OPTN/UNOS data, Ison and 
Nalesnik46 observed that in many instances in the US, 
deceased donor kidneys with small renal cell carcinomas 
were discarded and, in many cases, the contralateral kidney 
was discarded as well. However, in 75 patients who did 
receive organs (usually a liver or the contralateral kidney) 
from such donors, there have been no reports of malignancy 
in any recipient. Follow-up time has been limited to 45 days 
(recently expanded by policy to 2 years) post-transplant, a 
factor that must be taken into consideration.
Prostate carcinoma
The American Cancer Society estimates 217,730 new 
cases of prostate cancer in the US in 2010.16 Worldwide, 
the GLOBOCAN2008 Project of the International Agency 
for Research on Cancer estimated 899,000 new cases of 
prostate cancer in 2008, with the highest incidence (104.2 
per 100,000) in the Australia/New Zealand region.47
Risk of tumor development is age-dependent, with the 
American Cancer Society estimating a 2%, 6%, and 8% 
risk of cancer in white males, and a 4%, 10%, and 11% 
risk in black males, in the 50–59, 60–69 and 70–79 year 
ranges, respectively. These figures are of concern, given 
the increasing use of elderly donors. In an evaluation of 
prostate glands from 340 organ donors, Yin et al20 found 
adenocarcinoma in a total of 41 (12%) donors, with 23.4% 
in the 50–59, 34.7% in the 60–69, and 45.5% frequency in 
the 70–81 year ranges.
Despite these figures, donor-associated prostate adeno-
carcinomas have only rarely been reported, with the original 
report by Loh et al48 frequently cited in the literature. The 
donor in that case had carcinoma extending into the semi-
nal vesicles with metastases to the pelvic lymph nodes and 
adrenal glands (Stage IV), discovered after heart transplant 
had begun.
Kauffman et al49 reported three organs transplanted from 
donor(s) with prostate carcinoma, with no evidence of trans-
mission, based on the OPTN/UNOS database. A more recent 
report from the UNOS DTAC covering the years 2005–2009 
showed five donors with prostate carcinoma, with no reports 
of confirmed malignancy transmission.50 Pretagostini et al,51 
reporting for the Italian Centro Nazionale Trapianti, found 
carcinoma of the prostate to be the commonest donor 
malignancy in their series, and reported no tumor transmis-
sion in organs recovered from three donors with in situ to 
intermediate degree tumors. They considered high degree 
prostate carcinoma a contraindication to transplant, but did 
not provide definitions of these terms.
In light of the near absence of case reports of donor 
associated prostate carcinomas despite increased use of 
elderly donors, it seems likely that small incidental prostate 
carcinomas restricted to the gland have extremely limited 
risk for transmission via standard organ transplantation. The 
same cannot be said for more advanced/metastatic tumors, 
although it would be presumptuous to be dogmatic with limited 
 evidence. It seems prudent to examine the area at the time of 
organ removal and consider biopsy only of suspicious masses 
involving the prostatic region or beyond. However, at present, 
there is no compelling evidence to recommend routine biopsy 
of the prostate at the time of organ donation (ie, in the absence 
of a palpable lesion), especially since frozen section may have 
decreased sensitivity in detection of malignancy, Gleason 
score, and presence of extracapsular extension.52
Melanoma
Transmission of melanoma by organ transplantation has been 
documented a number of times since the original report of 
Jeremy et al.53 The IPITTR series reported disease in 17 of 
20 recipients who had received organs from donors with 
generally unsuspected melanoma.54 In this patient group, it 
was pointed out that donor melanoma often masqueraded 
as a primary central nervous system tumor or unexplained 
intracranial hemorrhage. An update of this series in the con-
text of cardiothoracic transplantation again concluded that 
melanomas have a high rate of transmission with subsequent 
high recipient morbidity and mortality.55
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The American Cancer Society has estimated 68,130 
new cases of skin melanomas in 2010, and many of these 
will have been excised while the tumor is relatively small. 
Questions regarding potential organ donation in such cases 
remain unanswered. However, several factors should be 
considered. First, tumor thickness values do not represent 
discrete thresholds of tumor progression, and the correla-
tion of thickness to risk of metastatic disease represents a 
continuous variable.56 Second, not only tumor thickness, 
but also mitotic rate, can lead to upstaging of a melanoma. 
Since this is a recently introduced modification to the 
American Joint Cancer Committee staging system,56 it is 
possible that a tumor previously considered as stage Ia is 
actually stage Ib. Third, Mocellin et al57 conducted a meta-
analysis that showed 32% of stage I melanomas already 
 demonstrated circulating tumor cells; indeed, one study 
showed circulating melanoma cells in a proportion of 
patients with stage 0 (in situ) melanoma,58 and circulating 
benign nevus cells have also been identified,59 raising the 
possibility that this might be a characteristic of melanocytes 
in general. Such findings, of unknown clinical significance 
at present, urge caution in this area.
A separate issue relates to patients with a history of remote 
or “cured” melanoma. We are again limited to anecdotal 
information that indicates that even melanomas ,1 mm 
thickness have a small risk of ultra late (.15 years) 
recurrence.60 Hypothetically, this may reflect a prolonged 
equilibrium between small numbers of circulating tumor cells 
and the donor host immune system.11 Also hypothetically, 
this balance may dissipate in the setting of organ transplan-
tation and immunosuppression. As circumstantial evidence, 
transmission of melanoma has been documented at 1661 and 
3262 years after curative resection in individual cases. In the 
first case, the original tumor was 2.6 mm thick, and in the 
second case size was not reported.
At present it seems reasonable to conclude, as others have 
done, that any patient with invasive melanoma should not 
serve as an organ donor. Further, there is no clear evidence 
to indicate that potential donors with in situ melanoma are 
not without risk. Because risk of tumor transmission extends 
to patients with a remote history of melanoma, skin exami-
nation for scars that may indicate past curative resection, 
and close attention to questions regarding previous removal 
of suspicious skin lesions, are important parts of the donor 
screening process. These steps are particularly important in 
the setting of donors with presumed central nervous system 
hemorrhage, because such lesions may mask underlying 
metastatic melanoma.
The issue of donor melanoma transmission has recently 
been reviewed in depth by Strauss and Thomas,11 who also 
concluded that any patient with active or remote “cured” 
melanoma should not serve as an organ donor.
Special considerations for donors 
with benign tumors
Although benign tumors by definition lack the malignant 
potential of fully developed cancer, several points are worth 
noting. First, such tumors may be present in the donor organ 
itself, raising questions of suitability. There are several 
case reports of successful transplantation of livers with 
giant hemangiomas, with or without resection in individual 
cases.63–67 In contrast, the use of donor hearts containing 
benign atrial myxomas is questioned by some authors,68–70 
and indeed, primary benign tumors themselves may provide 
a reason for heart transplantation.71,72
Other benign tumors have the potential to undergo malig-
nant transformation, and this should be kept in mind when 
such tumors are encountered. For example, some hepatocellu-
lar adenoma subtypes (particularly beta-catenin- expressing73) 
have a significant risk of hepatocellular carcinoma, and 
some typically benign tumors of nontransplant organs, such 
as salivary gland pleomorphic adenoma, bladder paragan-
glioma or adrenal pheochromocytoma, may evolve into 
malignant tumors. Renal oncocytomas and angiomyolipomas 
may rarely coexist with renal cell carcinoma. Finally, some 
benign lesions may be confused with malignancies. One such 
example is adrenal heterotopia occurring on the renal capsule, 
where the possibility of misdiagnosis as renal cell carcinoma 
exists. Any of the above circumstances has the potential to 
lead to nonoptimal triage of donor organs.
Potential donors with a history  
of cancer
OPTN/UNOS data on past history of cancer in potential 
organ donors in the US were first summarized and later 
updated by Kauffman et al.49,74,75 Overall, a total of 1069 
donors provided 2508 organs. Of those tumors that were 
specified, the ten resulting in the most frequent organ 
allografts (number of transplants in parentheses) included 
nonmelanoma skin cancer (776), uterine cervical cancer 
(336), glioblastoma multiforme (175), astrocytoma (152), 
melanoma (140), breast cancer (126), meningioma (80), 
ovarian carcinoma (75), prostate carcinoma (66), and endo-
metrial carcinoma (65).74 The only reported tumor transmis-
sion involved a donor with a history of melanoma 32 years 
prior, with transmission in one of six organ  recipients. It is 
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not clear whether this represents the patient later reported 
by Bajaj et al.62
Although the absolute frequency of tumor transmission 
from this donor cohort is low, the limitations of the data must 
be kept in mind. The grades and stages of tumors were not 
reported, and in many cases the specific diagnosis of tumor 
type itself was not available. The possibility of underreporting 
also exists, and the authors expressed concern regarding the 
use of donors with a history of tumors that may exhibit late 
recurrence, such as lymphoma or carcinomas arising from 
the breast, lung, colon, or kidney. They also maintained the 
position that a history of melanoma represents an absolute 
contraindication for organ donation.74
At present, reference to disease-free survival figures 
provides the best surrogate marker that a cancer may have 
been “cured”; survival figures alone do not incorporate 
information regarding rate of recurrence but may represent 
the only available information in some cases.
Feng et al10 used low frequency of tumor recurrence 
and high survival as surrogate markers in their discussion 
of donors with a history of breast or colon carcinoma. They 
concluded that potential donors with a history of either breast 
or colon carcinoma in situ (stage 0) could provide organs 
without any disease-free waiting period, but donors with 
a history of stage 1 (T1–T2) colon cancer would require a 
variable disease-free interval, or may never be able to serve 
as donors, depending upon differences in tumor recurrence 
and survival rates based on gender and race. In the case of 
stage 1 breast carcinoma, patients with T1a or T1b cancer 
could donate after a 10-year wait period, whereas those with 
tumor stage T1c or higher would not be eligible to donate 
regardless of wait period.10
The DTAC Malignancy Subcommittee8 considered any 
individuals with a history of melanoma, leukemia, lym-
phoma, or small cell carcinoma to be ineligible to serve 
as organ donors. In the case of a history of treated cancer 
(outside of central nervous system tumors), they suggested a 
5-year wait period, with those patients having a greater than 
99% chance of cure being considered low risk, and those 
with a probability of cure between 90% and 99% considered 
intermediate risk. Those patients with cure probabilities 
below these cutoffs, or with insufficient evidence on which 
to base a conclusion, were considered high risk donors.
Management-related issues
It is beyond the scope of this article to examine specific 
 management issues in the setting of donor-transmitted 
 neoplasia, and discussion is limited to a few brief points.
First, it is important to report any event in which donor-
transmitted malignancy is suspected, even if it is not yet 
proven. The OPTN requires reporting of such events to 
the OPTN Disease Transmission Advisory Committee, 
which can facilitate dissemination of information to those 
involved in the care of other recipients of organs or tis-
sues from the same donor (http://optn.transplant.hrsa.gov/
members/ committeesDetail.asp?ID=95). Reporting can be 
done through UNetSM (https://portal.unos.org/). This com-
mittee can provide general discussion related to assessing 
the likelihood that a given tumor represents a donor origin 
tumor, as well as recipient evaluation and management, on 
request. Expertise in this area also exists at the Israel Penn 
International Transplant Tumor Registry (http://www.ipittr.
org/Home.htm).
Patient outcome is dependent upon tumor type, among 
other things. Kauffman et al76 reviewed OPTN data to esti-
mate 46% overall mortality from donor transmitted tumors. 
However, that estimate represents six deaths in 15 recipients, 
with four of six deaths due to melanomas. A more recent 
review50 of OPTN donor tumor transmission data for the 
period 2005–2007 inclusive also found six recipient deaths, 
with four of six due to lymphoma. This suggests that a small 
number of tumor types contribute disproportionately to 
recipient mortality.
Conversion to rapamycin or other mammalian target 
of rapamycin (mTOR) inhibitor has been suggested in the 
setting of post-transplant malignancy.77–79 The immuno-
suppressed status of the recipient must also be taken into 
account if chemotherapeutic drugs are considered, and 
disease-specific survival for several tumor types is worse 
in the transplant population than in nontransplant patients 
with similar tumors matched for stage.17 For these reasons, 
oncologic consultation is generally advisable.
Summary
Potential organ donors with active or historical cancer 
comprise a heterogeneous population that cannot be evaluated 
for donation a priori. High level evidence is difficult to come 
by in this area; nevertheless extensive experience has shown 
that organs from individuals with metastatic carcinoma, 
sarcoma, melanoma, or small cell carcinoma should probably 
never be used for transplant. In contrast, patients with primary 
central nervous system tumors, prostate carcinoma, or small 
renal cell carcinomas must be assessed on an individual 
basis, and the literature documents numerous recipients with 
successful outcomes who have received organs donated by 
individuals with these conditions.
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The possibility of cancer should be entertained in every 
donor, particularly in unusual settings such as unexplained 
central nervous system hemorrhage, which may mask 
primary or metastatic malignancy.80 Evaluation of such 
donors requires an objective assessment of the tumor param-
eters along with a realistic evaluation of transmission risk 
potential and a monitoring and treatment strategy for the 
post-transplant period. Parallel evaluation of the recipient 
is essential, and includes consideration of the urgency of 
transplant as well as the active participation, consent, and 
understanding of the recipient regarding the overall risks 
and benefits.
The question originally raised by the title can be answered 
by applying the fundamental precept, primum non nocere, 
and recalling that harm may be avoided either by withholding 
a dangerous organ, or by performing a life-saving transplant 
using an organ that best clinical judgment says is appropriate 
to use in that circumstance.
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